Westover Capital Advisors LLC Purchases 172 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Westover Capital Advisors LLC lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,214 shares of the company’s stock after acquiring an additional 172 shares during the period. Westover Capital Advisors LLC’s holdings in Medpace were worth $2,147,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC lifted its position in Medpace by 4.9% during the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after purchasing an additional 26 shares during the period. Commonwealth Equity Services LLC lifted its holdings in shares of Medpace by 0.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after buying an additional 32 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Medpace by 5.3% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock worth $316,000 after buying an additional 39 shares during the last quarter. Journey Advisory Group LLC grew its holdings in shares of Medpace by 1.9% in the second quarter. Journey Advisory Group LLC now owns 2,390 shares of the company’s stock worth $984,000 after acquiring an additional 44 shares during the period. Finally, Coldstream Capital Management Inc. grew its holdings in shares of Medpace by 5.0% in the fourth quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock worth $292,000 after acquiring an additional 45 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Stock Up 2.0 %

Shares of NASDAQ:MEDP opened at $351.67 on Friday. The firm has a fifty day simple moving average of $384.27 and a two-hundred day simple moving average of $393.43. Medpace Holdings, Inc. has a 52 week low of $227.21 and a 52 week high of $459.77. The stock has a market capitalization of $10.90 billion, a P/E ratio of 35.85, a PEG ratio of 1.74 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. The firm had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The company’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.93 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on MEDP shares. TD Cowen cut their price target on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Guggenheim reduced their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Mizuho started coverage on shares of Medpace in a research note on Tuesday, May 28th. They set a “buy” rating and a $435.00 price target on the stock. Robert W. Baird cut their price objective on shares of Medpace from $469.00 to $430.00 and set an “outperform” rating for the company in a research report on Wednesday, July 24th. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Wednesday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $423.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.